Gary Nachman
Stock Analyst at Raymond James
(2.99)
# 1,334
Out of 5,146 analysts
97
Total ratings
58.9%
Success rate
6.05%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $80.93 | +9.97% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $18.60 | +2.15% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $13.22 | +278.21% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $226.92 | +10.17% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $384.33 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.59 | +672.20% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $11.80 | +137.29% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $327.36 | -8.97% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.62 | +332.90% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $23.46 | +57.72% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $46.97 | -36.13% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $4.14 | +69.08% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $196.83 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $14.58 | -72.57% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $12.32 | +143.51% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.19 | +903.13% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $16.08 | -12.94% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $33.62 | -70.26% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $34.62 | -13.34% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $4.29 | +17,382.52% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.11 | +30.93% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $27.97 | -24.92% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $80.93
Upside: +9.97%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $18.60
Upside: +2.15%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $13.22
Upside: +278.21%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $226.92
Upside: +10.17%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $384.33
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.59
Upside: +672.20%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $11.80
Upside: +137.29%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $327.36
Upside: -8.97%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.62
Upside: +332.90%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $23.46
Upside: +57.72%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $46.97
Upside: -36.13%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.14
Upside: +69.08%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $196.83
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $14.58
Upside: -72.57%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $12.32
Upside: +143.51%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.19
Upside: +903.13%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $16.08
Upside: -12.94%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $33.62
Upside: -70.26%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $34.62
Upside: -13.34%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $4.29
Upside: +17,382.52%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.11
Upside: +30.93%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $27.97
Upside: -24.92%